New Keytruda Combo Wins Funding In England For NSCLC
Executive Summary
MSD’s Keytruda will be paid for through the Cancer Drugs Fund for use in combination with carboplatin and paclitaxel as a first-line treatment for metastatic squamous non-small-cell lung cancer.
You may also be interested in...
Scottish HTA OKs Neratinib For Early-Stage Breast Cancer
A product that was initially turned down for marketing approval in the EU has now been given the green light for use on the National Health Service in Scotland, following a similar recommendation in England late last year.
New Price Helps Secure Funding For Rubraca In England
Clovis Oncology’s ovarian cancer treatment Rubraca is the latest PARP inhibitor to get the all-clear from the health technology assessment body, NICE.
Pierre Fabre Boosts Oncology Offering In Europe With Puma Deal
Another major deal with a US biotech has seen France’s Pierre Fabre exclusively licensing Puma’s Nerlynx for development and commercialization in Europe.